The ImmuBridge™ platform embodies cutting-edge advancements in oncology and immunotherapy. Leveraging this platform, we can develop trispecific antibodies targeting a variety of immune and tumor cell antigens to activate diverse immune mechanisms, fostering precise and efficient cancer therapeutics.
Kreirajte novu ponudu
Prijavi ovu stranicu
Stopa Trispecific Antibody Development
Kreiraj posao
Uredi ponudu
Dodajte razinu
Izbrišite svoju razinu
Jeste li sigurni da želite izbrisati ovu razinu?
Recenzije
Kako biste prodali svoj sadržaj i postove, počnite s stvaranjem nekoliko paketa. Monetizacija
